Genetic screens to study the immune system in cancer.

Genetic screens to study the immune system in cancer. Curr Opin Immunol. 2016 Jun 13;41:55-61 Authors: Wucherpfennig KW, Cartwright AN Abstract RNA interference and CRISPR/Cas9 technologies now enable systematic discovery of genes that regulate key pathways in the complex interaction between immune cells and tumor cells. Discovery screens are feasible in an in vivo setting, allowing identification of genes that limit the effectiveness of anti-tumor immunity. In vivo discovery screens can be informed by single-cell RNA-seq experiments that define the differentially expressed genes between functionally distinct immune cell subpopulations, both in humans and relevant animal models. Novel targets for cancer immunotherapy are being defined by the in depth functional annotation of immunosuppressive pathways in the tumor microenvironment. PMID: 27309352 [PubMed - as supplied by publisher]
Source: Current Opinion in Immunology - Category: Allergy & Immunology Authors: Tags: Curr Opin Immunol Source Type: research

Related Links:

Publication date: March 2020Source: Journal of Vascular and Interventional Radiology, Volume 31, Issue 3, SupplementAuthor(s): B. Choi, H. Jung, B. Yu, H. Choi, J. Lee, D. Kim
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
AbstractAnti ‐programmed cell death 1 (PD‐1) and its ligand (PD‐L1) has emerged as a novel immunotherapy for non‐small cell lung cancer (NSCLC). However, the proportion of patients who may benefit from immunotherapy is limited and the factors sensitive or resistant to immunotherapy are not completely cle ar. Therefore, to identify reliable biomarkers as predictors of clinical response and resistance to anti‐PD‐1/PD‐L1 therapies have become increasingly important. Here, we report a case of a patient with bone metastatic NSCLC, who achieved a pathologic complete response after preoperative pembr olizumab treatm...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Authors: Rossi G, Zullo L, Cerbone L, Coco S, Longo L, Tagliamento M, Dal Bello MG, Boccardo S, Alama A, Genova C Abstract Introduction: Poly (ADP-ribose) polymerase inhibitors (PARPi) are already part of the armamentarium of drugs available against ovarian and breast cancer. There is less data available on the efficacy of these drugs in the treatment of non-small cell lung cancer (NSCLC).Areas covered: The authors have analyzed the preclinical studies that justified the use of PARPi in NSCLC. They then evaluate the in vivo efficacy of the combination of these drugs with chemotherapy, radiotherapy, and immunotherap...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Publication date: Available online 20 February 2020Source: Mutation Research/Fundamental and Molecular Mechanisms of MutagenesisAuthor(s): M. Iida, P.M. Harari, D.L. Wheeler, M. ToulanyAbstractThe serine/threonine kinase AKT, also known as protein kinase B (PKB), is the major substrate to phosphoinositide 3-kinase (PI3K) and consists of three paralogs: AKT1 (PKBα), AKT2 (PKBβ) and AKT3 (PKBγ). The PI3K/AKT pathway is normally activated by binding of ligands to membrane-bound receptor tyrosine kinases (RTKs) as well as downstream to G-protein coupled receptors and integrin-linked kinase. Through multiple do...
Source: Mutation Research Fundamental and Molecular Mechanisms of Mutagenesis - Category: Cytology Source Type: research
Conditions:   Gastric Cancer;   Gastro-oesophageal Junction Cancer;   Immunotherapy;   Regorafenib;   Toripalimab Intervention:   Drug: Regorafenib Plus Toripalimab Sponsor:   Shanghai Changzheng Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study aimed to evaluate whether IRE combining indoleamine 2,3-dioxygenase inhibitor (IDOi, Epacadostat) loaded iron oxide nanocarriers (IDOi-INCs) can serve as a magnetic resonance imaging (MRI) –guided local ablation strategy for enhancing prostate cancer immunotherapy.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Scientific Session 12 Source Type: research
To evaluate the potential of sequential MR image –guided local immune checkpoint blockade immunotherapy using multifunctional carriers after a prechemotherapy in prostate cancer (PC).
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Scientific Traditional Poster Source Type: research
Authors: Morita S, Mochizuki M, Shibuya-Takahashi R, Nakamura-Shima M, Yamazaki T, Imai T, Asada Y, Matsuura K, Kawamura S, Yamaguchi K, Yasuda J, Sugamura K, Katori Y, Satoh K, Tamai K Abstract CD271 is a common receptor for all neurotrophins that is localized to neurons, endothelial cells, and the basal layer of the epithelium in normal tissue. Recently, we and others reported that CD271 plays essential roles in the development of squamous cell carcinoma, especially in tumor-initiating cells. Since little is known about how CD271 regulates cancer cell initiation and proliferation, antibodies that recognize differ...
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research
German biopharmaceutical firm Immatics said on Thursday it plans to collaborate with British drugmaker GlaxoSmithKline (GSK) to develop immunotherapies targeting multiple cancer indications, with a focus on solid tumours.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Rogerio Lilenbaum, MD, talked about the state of lung cancer in regards to immunotherapy and targeted therapy at the 17th Annual Winter Lung Conference in Miami Beach, Florida.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Genetics | Immunotherapy | Study